Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacosamide Extension in Pediatric Epilepsy
NCT01964560Phase 3Completed
- Sponsor
- UCB
- Start
- Aug 2014
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 35
01
Overview
Phase 3, open-label, single-arm trial of lacosamide in focal onset seizure, sponsored by UCB. Primary endpoints: Percentage of Participants With Treatment-emergent Adverse Events at Week 104, Percentage of Participants With Serious TEAEs at Week 104 and 1 more. Started Aug 2014; status: completed.
02
Drugs
lacosamide
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT01964560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01964560.